Recovering from Opioid Use? Join Our Study
Yale University researchers are partnering with individuals who are currently receiving methadone or buprenorphine treatment for a research study aimed at understanding the effectiveness of cannabinoids as an additional treatment option.
Conducted at VA Connecticut Healthcare System, West Haven, CT
Compensation
Provided
Provided
currently receiving methadone or buprenorphine
18-70 Years Old
Fast Facts
Study Background
In 2019, nearly 50,000 people in the United States died from opioid-involved overdoses. The existing treatments for opioid use disorder (OUD) focus on preventing craving and withdrawal symptoms but do not fully address the risk for relapse.
Thus, researchers believe that there is a growing need to develop new treatment options for OUD. This research study explores the short-term effects of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), the main ingredient of cannabis, among persons with OUD who are receiving treatment with methadone or buprenorphine.
VA Connecticut / Project ID 1583127
Yale HIC # 2000027065
Thus, researchers believe that there is a growing need to develop new treatment options for OUD. This research study explores the short-term effects of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), the main ingredient of cannabis, among persons with OUD who are receiving treatment with methadone or buprenorphine.
VA Connecticut / Project ID 1583127
Yale HIC # 2000027065
Additional Information
Researchers believe that there is a growing need to develop new treatment options for OUD. This research study explores the short-term effects of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), the main ingredient of cannabis, among persons with OUD who are receiving treatment with methadone.
You may qualify to participate in this study if you meet the following criteria.
Key Criteria:
● Adults aged 18-70 years old who are diagnosed with opioid use disorder.
● Must be currently receiving methadone or buprenorphine maintenance treatment.
● Must have used cannabis at least once in the past, but currently does not use cannabis on a daily basis.
● Able to attend 4 study visits at the research site over approximately 3 weeks. This includes 1 screening visit and 3 test visits. Each test visit will be separated by at least 72 hours.
Key Criteria:
● Adults aged 18-70 years old who are diagnosed with opioid use disorder.
● Must be currently receiving methadone or buprenorphine maintenance treatment.
● Must have used cannabis at least once in the past, but currently does not use cannabis on a daily basis.
● Able to attend 4 study visits at the research site over approximately 3 weeks. This includes 1 screening visit and 3 test visits. Each test visit will be separated by at least 72 hours.
● This is not a treatment study. Although participants may experience temporary effects of the study medication, this is not to be expected to have long-term effects, as they will only receive a single dose on each test day.
● Participation will last about 6 hours per day for 3 test visits.
● During the test visits, participants will be asked to take medication containing a different dose, in a capsule form, each day. The study team can further elaborate on this.
● Participants will be asked to complete questionnaires and computer testing.
● Participation will last about 6 hours per day for 3 test visits.
● During the test visits, participants will be asked to take medication containing a different dose, in a capsule form, each day. The study team can further elaborate on this.
● Participants will be asked to complete questionnaires and computer testing.
Participants will be compensated up to $325 for participating in this study. An additional $20 will be compensated for any additional study visits requested.
There is no cost for you to participate in our research program.